Axsome believes that its current cash, along with the remaining committed capital from the $350 million term loan facility, is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan, which includes the continued commercialization of Sunosi and Auvelity. Axsome expects that its operating expenses will increase year over year as the Company commercializes Sunosi and Auvelity and continues to advance its pipeline.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXSM:
- Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Pharmanovia announces in-licensing agreement with Axsome for Sunosi
- Axsome Therapeutics enters license agreement with Pharmanovia
- Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
- Axsome facing Auvelity IP challenge ‘not a surprise,’ says BofA
